USA - engelsk - NLM (National Library of Medicine)

bryant ranch prepack - estrogens, esterified (unii: 3asp8q3768) (estrogens, esterified - unii:3asp8q3768), methyltestosterone (unii: v9efu16zif) (methyltestosterone - unii:v9efu16zif) - esterified estrogens and methyltestosterone full and half-strength tablets are indicated in the: esterified estrogens and methyltestosterone full and half-strength tablets should not be used in women with any of the following conditions: methyltestosterone should not be used in: methyltestosterone is classified as a schedule iii controlled substance under the anabolic steroids act of 1990.

USA - engelsk - NLM (National Library of Medicine)

bryant ranch prepack - estrogens, esterified (unii: 3asp8q3768) (estrogens, esterified - unii:3asp8q3768), methyltestosterone (unii: v9efu16zif) (methyltestosterone - unii:v9efu16zif) - esterified estrogens and methyltestosterone full and half-strength tablets are indicated in the: esterified estrogens and methyltestosterone full and half-strength tablets should not be used in women with any of the following conditions: methyltestosterone should not be used in: methyltestosterone is classified as a schedule iii controlled substance under the anabolic steroids act of 1990.

USA - engelsk - NLM (National Library of Medicine)

bryant ranch prepack - estrogens, esterified (unii: 3asp8q3768) (estrogens, esterified - unii:3asp8q3768), methyltestosterone (unii: v9efu16zif) (methyltestosterone - unii:v9efu16zif) - esterified estrogens and methyltestosterone full and half-strength tablets are indicated in the: - treatment of moderate to severe vasomotor symptoms associated with the menopause in those patients not improved by estrogens alone. (there is no evidence that estrogens are effective for nervous symptoms or depression without associated vasomotor symptoms, and they should not be used to treat such conditions.) - esterified estrogens and methyltestosterone full and half-strength tablets have not been shown to be effective for any purpose during pregnancy and its use may cause severe harm to the fetus. esterified estrogens and methyltestosterone full and half-strength tablets should not be used in women with any of the following conditions: - undiagnosed abnormal genital bleeding. - known, suspected, or history of cancer of the breast. - known or suspected estrogen-dependent neoplasia. - active deep vein thrombosis, pulmonary embolism or history of these conditions. - active or recent (e.g., within the past year)

USA - engelsk - NLM (National Library of Medicine)

centrix pharmaceutical, inc, - estrogens, esterified (unii: 3asp8q3768) (estrogens, esterified - unii:3asp8q3768), methyltestosterone (unii: v9efu16zif) (methyltestosterone - unii:v9efu16zif) - estrogens, esterified 1.25 mg - covaryxt® and covaryx® h.s. are indicated in the treatment of moderate to severe vasomotor symptoms associated with the menopause in those patients not improved by estrogens alone. (there is no evidence that estrogens are effective for nervous symptoms or depression without associated vasomotor symptoms, and they should not be used to treat such conditions.) covaryxt® and covaryx® h.s. have not been shown to be effective for any purpose during pregnancy and its use may cause severe harm to the fetus (see boxed warnings). estrogens should not be used in women with any of the following conditions: - known or suspected cancer of the breast except in appropriately selected patients being treated for metastatic disease. - known or suspected estrogen-dependent neoplasia. - known or suspected pregnancy (see boxed warnings). - undiagnosed abnormal genital bleeding. - active thrombophlebitis or thromboembolic disorders. - a past history of thrombophlebitis, thrombosis, or thromboembolic disorders associated with previ

USA - engelsk - NLM (National Library of Medicine)

bryant ranch prepack - estrogens, esterified (unii: 3asp8q3768) (estrogens, esterified - unii:3asp8q3768), methyltestosterone (unii: v9efu16zif) (methyltestosterone - unii:v9efu16zif) - esterified estrogens and methyltestosterone full and half-strength tablets are indicated in the: esterified estrogens and methyltestosterone full and half-strength tablets should not be used in women with any of the following conditions: methyltestosterone should not be used in: methyltestosterone is classified as a schedule iii controlled substance under the anabolic steroids act of 1990.

USA - engelsk - NLM (National Library of Medicine)

seton pharmaceuticals - estrogens, esterified (unii: 3asp8q3768) (estrogens, esterified - unii:3asp8q3768), methyltestosterone (unii: v9efu16zif) (methyltestosterone - unii:v9efu16zif) - esterified estrogens and methyltestosterone full and half-strength tablets are indicated in the: - treatment of moderate to severe vasomotor symptoms associated with the menopause in those patients not improved by estrogens alone. (there is no evidence that estrogens are effective for nervous symptoms or depression without associated vasomotor symptoms, and they should not be used to treat such conditions.) - esterified estrogens and methyltestosterone full and half-strength tablets have not been shown to be effective for any purpose during pregnancy and its use may cause severe harm to the fetus. esterified estrogens and methyltestosterone full and hall-strength tablets should not be used in women with any of the following conditions: - undiagnosed abnormal genital bleeding. - known, suspected, or history of cancer of the breast - known or suspected estrogen-dependent neoplasia - active deep vein thrombosis, pulmonary embolism or history of these conditions. - active or recent (e.g., within the past year) ar

USA - engelsk - NLM (National Library of Medicine)

avera mckennan hospital - estrogens, esterified (unii: 3asp8q3768) (estrogens, esterified - unii:3asp8q3768) - estrogens, esterified 0.625 mg

USA - engelsk - NLM (National Library of Medicine)

physicians total care, inc. - estrogens, esterified (unii: 3asp8q3768) (estrogens, esterified - unii:3asp8q3768) - estrogens, esterified 0.3 mg - menest is indicated in the: - treatment of moderate to severe vasomotor symptoms associated with the menopause. treatment of moderate to severe vasomotor symptoms associated with the menopause. - treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. when prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. when prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. - female hypogonadism. female hypogonadism. - female castration. female castration. - primary ovarian failure. primary ovarian failure. - breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. breast cancer (for palliation only) in appropriately selected women and men with metastatic disease

USA - engelsk - NLM (National Library of Medicine)

pfizer laboratories div pfizer inc - estrogens, esterified (unii: 3asp8q3768) (estrogens, esterified - unii:3asp8q3768) - estrogens, esterified 0.3 mg - menest is indicated in the: menest should not be used in women with any of the following conditions:

USA - engelsk - NLM (National Library of Medicine)

seton pharmaceuticals - estrogens, conjugated (unii: iu5qr144qx) (estrogens, conjugated - unii:iu5qr144qx) - estrogens, conjugated 0.625 mg